Broad Institute

MAY 9, 2024

Initially announced in March 2015, this renewed agreement extends the collaboration until September 2029 and will continue to support ongoing programs focused on the biology and genetics of aging as well as early-stage drug discovery. Terms of the agreement were not disclosed. “We

Clinical Trials 52

Clinical Trials Clinical Development Disease Science 52

The Pharma Data

OCTOBER 9, 2021

Safety profile of deucravacitinib consistent with other trials and no new safety signals reported. Deucravacitinib has been shown to be a highly effective, first-in-class, oral, selective TYK2 inhibitor in psoriasis and we have ongoing Phase 3 trials exploring the potential of deucravacitinib in psoriatic arthritis,” said Samit Hirawat, M.D.

Disease 52

Disease Trials Science Immune Response 52

Vial

MARCH 1, 2024

Growth factors for this market included the growing size of the pharmaceutical industry, the increasing number of clinical trials , substantial funds dedicated to pharma and biotech R&D, and the growing biosimilars and generics market. billion by 2029. By revenue, the largest CRO in the US was Thermo Fisher Scientific Inc.,

Clinical Trials 52

Clinical Trials Clinical Research Trials Laboratories 52

Codon

FEBRUARY 23, 2025

After decades of research into therapies and preventive measures, though, global AIDS deaths have now fallen to about 600,000 annually. million new HIV infections by 2029, undermining progress toward the UN’s goal. By 1987, the FDA licensed zidovudine after trials showed it increased survival rates. million by 2004.

Clinical Trials 68

Clinical Trials Virus Vaccine Trials 68